Background
Materials and methods
Search strategy
Inclusion criteria and procedure
Assessment of methodological quality
Item | Description |
---|---|
1 | Was the method of randomization adequate? |
2 | Was the treatment allocation concealed? |
3 | Were the groups similar at baseline regarding the most important prognostic indicators? |
4 | Was the outcome assessor blinded to the intervention? |
5 | Were co-interventions avoided or similar? |
6 | Was the drop-out rate described and acceptable? |
7 | Was the timing of the outcome assessment similar in all groups? |
8 | Did the analysis include an intention-to-treat analysis? |
Statistical analysis
Strong evidence | Consistent findings among multiple high-quality trials* |
Moderate evidence | Consistent findings in multiple low-quality trials and/or one high-quality trial |
Limited evidence | Consistent findings in at least one low-quality trial |
Conflicting evidence | Inconsistent findings among multiple trials (high- and/or low-quality trials) |
No evidence | Findings of eligible trials do not meet the criteria for one of the levels of evidence stated above, or there are no eligible trials available |
Results
Selection of studies
Methodological quality
Fulfilled validity criteria | Unfulfilled validity criteria | Incomplete information for validity assessment | Internal validity score | Methodological quality | ||||
---|---|---|---|---|---|---|---|---|
Study | Selection bias (1,2,3) | Performance bias (5) | Attrition bias (6,8) | Detection bias (4,7) | ||||
MIS
| ||||||||
Lawlor et al. [31] | 1,2,3 | 5 | 6 | 4,7 | 8 | - | 7 | High |
Chimento et al. [4] | 1,2,3 | 5 | 6 | 4,7 | 8 | - | 7 | High |
Ogonda et al. [34] | 1,2,3 | 5 | 6 | 4,7 | 8 | - | 7 | High |
Kim [30] | 1,3 | 5 | 6 | 4,7 | 2,8 | - | 6 | High |
Bennett et al. [22] | 3 | 5 | 6 | 4,7 | 8 | 1,2 | 5 | Medium |
Chung et al. [23] | 3 | 5 | 6 | 4,7 | 1,2,8 | - | 5 | Medium |
Khan et al. [29] | 3 | 5 | 6 | 4,7 | 1,2,8 | - | 5 | Medium |
Dorr et al. [26] | 3 | 5 | 6 | 4,7 | 8 | 1,2 | 5 | Medium |
Ciminiello et al. [24] | 3 | 5 | 6 | 7 | 1,2,4,8 | - | 4 | Medium |
Dutka et al. [27] | 3 | - | 6 | 4,7 | 1,2,8 | 5 | 4 | Medium |
Hart et al. [28] | 3 | - | 6 | 4,7 | 8 | 1,2,5 | 4 | Medium |
Mazoochian et al. [37] | 3 | 5 | - | 4,7 | 8 | 1,2,6 | 4 | Medium |
Rittmeister & Peters [35] | 3 | 5 | 6 | 7 | 1,2,4,8 | - | 4 | Medium |
Speranza et al. [36] | 3 | 5 | 6 | 7 | 4,8 | 1,2 | 4 | Medium |
DiGioia et al. [17] | 3 | 5 | - | 4,7 | 1,2,8 | 6 | 4 | Medium |
De Beer et al. [25] | 3 | - | 6 | 7 | 1,2,4,8 | 5 | 3 | Medium |
Levine et al. [32] | 3 | - | 6 | 7 | 1,2,4,5,8 | - | 3 | Medium |
Nakamura et al. [33] | 3 | - | 6 | 7 | 1,2,4,5,8 | - | 3 | Medium |
CAS
| ||||||||
Leenders et al. [16] | 1,2,3 | 5 | 6 | 4,7 | 8 | - | 7 | High |
Parratte & Argenson [40] | 1,2,3 | 5 | 6 | 4,7 | 8 | - | 7 | High |
Kalteis et al. [15] | 1,3 | 5 | 6 | 4,7 | 8 | 2 | 6 | High |
Kalteis et al. [38] | 1,3 | 5 | 6 | 7 | 8 | 2,4 | 5 | Medium |
Sugano et al. [41] | 3 | 5 | 6 | 4,7 | 1,2,8 | - | 5 | Medium |
Najarian et al. [39] | 3 | 5 | 6 | 7 | 1,2,8 | 4 | 4 | Medium |
Wixson & MacDonald [18] | 3 | 5 | 6 | 7 | 1,2,8 | 4 | 4 | Medium |
Operative time
Operative time | Intraoperative blood loss | Length of Stay | |||
---|---|---|---|---|---|
Study | Methodological quality | No. of patients | SMD (95% CI) | SMD (95% CI) | SMD (95% CI) |
MIS
| |||||
Chimento et al. [4] | High | 60 | 0.03 (-0.48, 0.54) | -0.74 (-1.26, -0.21) | NE (NS) |
Ogonda et al. [34] | High | 219 | -0.49 (-0.76, -0.22) | -0.29 (-0.56, -0.03) | NE (NS) |
Kim [30] | High | 140 | NE (S, decrease) | NE (NS) | NR |
Chung et al. [23] | Medium | 120 | -0.42 (-0.79, -0.06) | -1.18 (-1.56, -0.79) | -0.73 (-1.10, -0.36) |
Khan et al. [29] | Medium | 200 | -0.01 (-0.29, 0.26) | -0.84 (-1.13. -0.55) | NR |
Dorr et al. [26] | Medium | 60 | -0.32 (-0.83, 0.19) | -0.41 (-0.92, 0.10) | -0.53 (-1.03, -0.03) |
Ciminiello et al. [24] | Medium | 120 | NE (NS) | NE (NS) | NE (NS) |
Dutka et al. [27] | Medium | 120 | -0.88 (-1.25, -0.50) | -1.40 (-1.80, -1.00) | NE (NS) |
Hart et al. [28] | Medium | 120 | NE (NS) | NR | NR |
Mazoochian et al. [37] | Medium | 52 | NE (S, decrease) | NE (S, decrease) | NR |
Rittmeister & Peters [35] | Medium | 152 | NE (NS) | NE (NS) | NR |
Speranza et al. [36] | Medium | 100 | NE (NS) | NE (S, decrease) | NE (NS) |
DiGioia et al. [17] | Medium | 70 | NE (NS) | NR | NE (NS) |
De Beer et al. [25] | Medium | 60 | NE (NS) | -0.77 (-1.30, -0.25) | NE (NS) |
Levine et al. [32] | Medium | 201 | NE (S, decrease) | NE (NS) | NE (S, decrease) |
Nakamura et al. [33] | Medium | 92 | -0.85 (-1.28, -0.42) | -0.42 (-0.84, -0.01) | NR |
CAS
| |||||
Kalteis et al. [15] (CT-based) | High | 60 | NE (S, increase) | NR | NR |
Kalteis et al. [15] (Imageless) | High | 60 | NE (NS) | NR | NR |
Kalteis et al. [38] | Medium | 45 | 0.45 (-0.14, 1.04) | NR | NR |
Sugano et al. [41] | Medium | 180 | NE (S, increase) | NE (NS) | NR |
Najarian et al. [39] | Medium | 100 | NE (S, increase) | NE (S, decrease) | NR |
Intraoperative blood loss
Length of stay
Complications
No. of complications | No. of outliers | ||||||
---|---|---|---|---|---|---|---|
Study | Methodological quality | Study group | Control group | OR (95% CI) | Study group | Control group | OR (95% CI) |
MIS
| |||||||
Lawlor et al. [31]†
| High | 3/109 | 4/110 | 0.75 (0.16, 3.43) | NR | ||
Chimento et al. [4] | High | 3/28 | 2/32 | 1.80 (0.28, 11.64) | 0 | 0 | - |
Ogonda et al. [34]†
| High | 3/109 | 6/110 | 0.75 (0.16, 3.43) | 16/105 | 19/109 | 0.85 (0.41, 1.76) |
Kim [30] | High | 3/70 | 2/70 | 1.52 (0.25, 9.40) | 13/70 | 11/70 | 1.22 (0.51, 2.95) |
Chung et al. [23] | Medium | 3/57 | 5/55 | 0.58 (0.13, 2.54) | 0 | 0 | - |
Khan et al. [29] | Medium | 15/100 | 21/100 | 0.66 (0.32, 1.38) | 3/100 | 3/100 | 1.00 (0.20, 5.08) |
Dorr et al. [26] | Medium | 2/30 | 3/30 | 0.64 (0.10, 4.15) | 0 | 0 | - |
Ciminiello et al. [24] | Medium | 0 | 0 | - | 0 | 0 | - |
Dutka et al. [27] | Medium | 1/60 | 1/60 | 1.00 (0.06, 16.37) | 0 | 0 | - |
Hart et al. [28] | Medium | 1/60 | 1/60 | 1.00 (0.06, 16.37) | 0 | 0 | - |
Mazoochian et al. [37] | Medium | 4/26 | 3/26 | 1.39 (0.28, 6.95) | NR | ||
Rittmeister & Peters [35] | Medium | 7/76 | 6/76 | 1.18 (0.38, 3.70) | NR | ||
Speranza et al. [36] | Medium | 3/46 | 0/54 | 8.77 (0.44, 174.38) | 1/46 | 3/54 | 0.38 (0.04, 3.76) |
DiGioia et al. [17] | Medium | 0 | 0 | - | 0 | 0 | - |
De Beer et al. [25] | Medium | 1/30 | 2/30 | 0.48 (0.04, 5.63) | 0 | 0 | - |
Levine et al. [32] | Medium | 14/126 | 13/75 | 0.60 (0.26, 1.35) | NR | ||
Nakamura et al. [33] | Medium | 1/50 | 2/42 | 0.41 (0.04, 4.67) | 4/50 | 5/42 | 0.64 (0.16, 2.57) |
CAS
| |||||||
Leenders et al. [16] | High | NR | 7/50 | 14/50 | 0.42 (0.15, 1.15) | ||
Parratte & Argenson [40] | High | 0 | 0 | - | 6/30 | 17/30 | 0.19 (0.06, 0.60) |
Kalteis et al. [15] (CT-based) | High | 0/30 | 1/30 | 0.32 (0.01, 8.24) | 5/30 | 16/30 | 0.17 (0.05, 0.58) |
Kalteis et al. [15] (Imageless) | High | 0/30 | 1/30 | 0.32 (0.01, 8.24) | 2/30 | 16/30 | 0.06 (0.01, 0.31) |
Kalteis et al. [38] | Medium | 0 | 0 | - | 2/23 | 11/22 | 0.10 (0.02, 0.51) |
Sugano et al. [41] | Medium | 0/60 | 7/120 | 0.13 (0.01, 2.23) | 0/59 | 31/111 | 0.02 (0.00, 0.36) |
Najarian et al. [39] | Medium | 2/47 | 2/53 | 1.13 (0.15, 8.38) | 6/47 | 18/53 | 0.28 (0.10, 0.80) |
Wixson & MacDonald [18] | Medium | 2/82 | 1/50 | 1.23 (0.11, 13.87) | 17/82 | 18/50 | 0.46 (0.21, 1.02) |
Acetabular outliers
Physical functioning
Physician-reported physical functioning
Follow-up | |||||
---|---|---|---|---|---|
Study | Methodological quality | 6 weeks | 3 months | 6 months | 1 year |
Physician-reported
| |||||
Ogonda et al. [34] * | High | 0.08 (-0.18, 0.35) | NR | NR | NR |
Dorr et al. [26] * | Medium | NE (NS) | NR | NE (NS) | NR |
Ciminiello et al. [24] * | Medium | 0.26 (-0.10, 0.62) | NR | NR | NR |
Dutka et al. [27] * | Medium | NE (S) a
| NE (NS) | NE (NS) | NR |
Speranza et al. [36] * | Medium | NR | NE (NS) | NE (NS) | NR |
Hart et al. [28]†
| Medium | NR | NE (S) a
| NE (NS) | NE (NS) |
Mazoochian et al. [37] * | Medium | NE (NS) | NE (S) a
| NR | NR |
DiGioia et al. [17] * | Medium | NR | NE (S) a
| NE (S) a
| NE (NS) a
|
De Beer et al. [25] * | Medium | 0.40 (-0.11, 0.91) | NR | NR | NR |
Nakamura et al. [33]†
| Medium | NR | NR | NE (NS) | NR |
Patient-reported
| |||||
Ogonda et al. [34]‡
| High | 0.03 (-0.23, 0.30) | NR | NR | NR |
Ogonda et al. [34]§
| High | 0.13 (-0.13, 0.40) | NR | NR | NR |
Ogonda et al. [34] ** | High | 0.01 (-0.26, 0.27) | NR | NR | NR |
Khan et al. [29]‡
| Medium | NR | NE (S) a
| NR | NE (S) a
|
Khan et al. [29]††
| Medium | NR | NE (NS) | NR | NR |
Mazoochian et al. [37]‡
| Medium | NE (S) a
| NE (S) a
| NR | NR |
Speranza et al. [36]‡
| Medium | NR | NE (NS) | NE (NS) | NR |
De Beer et al. [25]§
| Medium | 0.24 (-0.27, 0.74) | NR | NR | NR |
Gait analysis
b
| |||||
Lawlor et al. [31] | High | -0.10 (-0.37, 0.16) | NR | NR | NR |
Ogonda et al. [34] | High | 0.19 (-0.07, 0.46) | NR | NR | NR |
Bennet et al. [22] | Medium | NE (NS) | NR | NR | NR |
Dorr et al. [26] | Medium | NE (NS) | NE (NS) | NR | NR |
Patient-reported physical functioning
Gait analysis
Pain
Follow-up | |||||
---|---|---|---|---|---|
Study | Methodological quality | 6 weeks | 3 months | 6 months | 1 year |
Kim[30]* | High | NE (NS) | NE (NS) | NR | NE (NS) |
Dutka et al. [27] * | Medium | -0.51 (-0.87, -0.15) | -0.13 (-0.49, 0.23) | -0.31 (-0.67, 0.05) | NR |
Hart et al. [28]†
| Medium | NE (NS) | NR | NE (NS) | NE (NS) |
DiGioia et al. [17]‡
| Medium | NR | NE (NS) | NE (NS) | NE (NS) |
Nakamura et al. [33]†
| Medium | NR | NR | NE (NS) | NR |